CD<sup>+</sup><sub>8</sub>T细胞水平评价Ⅲ-Ⅳ期非小细胞肺癌放化疗预后价值

doi:10.3760/cma.j.cn113030-20200414-00180

Abstract
Figure/Table
References(34)
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective To explore the changes of CD⁺₈ T cells in stage Ⅲ-Ⅳ non-small cell lung cancer (NSCLC) patients before and after radiochemotherapy and evaluate its clinical value in predicting survival. Methods A total of 795 patients with stage Ⅲ-Ⅳ NSCLC who completed CD⁺₈ T cell testing from January 2011 to December 2017 were recruited (249 patients completed 1-3 tests within 6 months after treatment). The survival difference of patients with different levels of CD⁺₈ T cells and the prognostic value of the changes in the CD⁺₈ T cell level were analyzed. The survival analysis was performed by Kaplan-Meier method and log-rank test or univariate analysis. The multivariate survival analysis was conducted by Cox’s regression model. Results Before treatment, the levels of CD⁺₈ T cells in the peripheral blood did not significantly differ among patients with different clinical factors. The survival time of stage Ⅲ NSCLC patients with CD⁺₈ T cell levels of<26.44% was significantly prolonged (P=0.043). After treatment, the levels of CD⁺₈ T cells were significantly higher than those before treatment. The levels were similar within 1-3 months, decreased after 4-6 months but still significantly higher than those before treatment. The median survival time of patients with CD⁺₈cell levels of<43.90% after treatment was 22 months, significantly longer than 16 months of those with CD⁺₈cell levels of ≥43.90%(P=0.032). Stratified analysis demonstrated no significant difference in the survival time at 1 month and 2-3 months after treatment (P>0.05), whereas the survival time significantly differed at 4-6 months (P=0.001). The multivariate survival analysis showed that CD⁺₈ cell levels of<43.90% after treatment was an independent prognostic factor (HR=0.714, P=0.031). Conclusions The effect of CD⁺₈ T cells on prognosis of patients with stage Ⅲ-Ⅳ NSCLC is limited. After treatment, CD⁺₈ T cell levels are increased significantly. A certain increase in the CD⁺₈ T cell levels can prolong the survival time. The detection of CD⁺₈ T cell subtypes plays a more significant role.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Wang Haojie
	Wang Lixue
	Ouyang Weiwei
	Ma Zhu
	Li Qingsong
	Yang Wengang
	Li Huiqin
	Su Shengfa
	Lu Bing

Key words： Carcinoma, non-small cell lung/radiochemotherapy CD⁺₈ T cell Prognosis

Received: 14 April 2020

Corresponding Authors: Lu Bing, Email:lbgymaaaa@163.com

Cite this article:

Wang Haojie,Wang Lixue,Ouyang Weiwei et al. Prognostic value of peripheral blood CD⁺₈T lymphocytes for stage Ⅲ-Ⅳ non-small cell lung cancer patients treated with chemoradiotherapy[J]. Chinese Journal of Radiation Oncology, 2020, 29(10): 849-854.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.cn113030-20200414-00180 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2020/V29/I10/849

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. DOI:10.3322/caac.21492.
[2] Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):112-115. DOI:10.3322/caac.21338.
[3] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017[J]. CA:Cancer J Clin, 2017, 67(1):7-30. DOI:10.3322/caac.21387.
[4] O′Rourke N, Figuls MR, Bernadó NF, et al. Concurrent chemoradiotherapy in non-small cell lung cancer[J]. Cochrane Data System Rev, 2010, 6(6):CD002140. DOI:10.1002/14651858. CD002140.pub3.
[5] Lu B, Li HQ, Geng YC, et al. Overall survival and toxicities regarding thoracic three-dimensional radiotherapy with concurrent chemotherapy for stage ⅠV non-small cell lung cancer:results of a prospective single-center study[J]. BMC Cancer, 2013, 13:474. DOI:10.1186/1471-2407-13-474.
[6] Soukup K, Wang X. Radiation meets immunotherapy-a perfect match in the era of combination therapy?[J]. Int J Radiat Biol, 2015, 91(4):1-15. DOI:10.3109/09553002.2014.995383.
[7] Golden EB, Apetoh L. Radiotherapy and immunogenic cell death[J]. Sem Radiat Oncol, 2015, 25(1):11-17. DOI:10.1016/j.semradonc.2014.07.005.
[8] Ma Y, Kepp O, Ghiringhelli F, et al. Chemotherapy and radiotherapy:cryptic anticancer vaccines[J]. Semin Immunol, 2010, 22(3):113-124. DOI:10.1016/j.smim.2010.03.001.
[9] Fridman WH, Pagès F, Sautès-Fridman C, et al. The immune contexture in human tumours:impact on clinical outcome[J]. Nat Rev Cancer, 2012, 12(4):298-306. DOI:10.1038/nrc3245.
[10] Nishihira M, Nakazato Y, Maeda S, et al. Impact of tumor infiltrating lymphocytes and lymphoid follicle formation on patient survival following surgery for lung squamous cell carcinoma[J]. Thorac Cancer, 2019, 10(2):219-225. DOI:10.1111/1759-7714.12935.
[11] Antonia S, Villegas A, Daniel D, et al. PL02.01 overall survival with durvalumab versus placebo after chemoradiotherapy in stage Ⅲ NSCLC:updated results from pacific[J]. J Thoracic Oncol, 2018, 13(10):S184-S188. DOI:10.1016/j.jtho.2018.08.010.
[12] Jaden DE, Lindsay KM, Zhang HN, et al. Prospective immunophenotyping of CD₈ T cells and associated clinical outcomes of patients with oligometastatic prostate cancer treated with metastasis-directed SBRT[J]. Int J Radiat Oncol Biol Phys, 2019, 103(2):229-240. DOI:10.1016/j.ijrobp.2018.09.001.
[13] Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours:Revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2):247. DOI:10.1016/j.ejca.2008.10.026.
[14] 石艳芬, 陈梅英, 苏文芳. 肿瘤患者外周血 T 淋巴细胞亚群和自然杀伤细胞数目的变化及其临床意义[J]. 检验医学与临床, 2012, 22:2888-2889. DOI:103969/j.issn.1672-9455.2012.22.061.
Shi YF, Chen MY, Su WF. Changes of T lymphocyte subsets and natural killer cell numbers in peripheral blood of tumor patients and their clinical significance[J]. Labor Med Clin, 2012, 22:2888-2889. DOI:103969/j.issn.1672-9455.2012.22.061.
[15] Arum CJ, Anderssen E, Viset T, et al. Cancer immunoediting from immunosurveillance to tumor escape in microvillus-formed niche:a study of syngeneic orthotopic rat bladder cancer model in comparison with human bladder cancer[J]. Neoplasia, 2010, 12(6):434-442. DOI:10.1593/neo.91824.
[16] Jadus MR, Natividad J, Mai A, et al. Lung cancer:a classic example of tumor escape and progression while providing opportunities for immunological intervention[J]. Clin Develop Immunol, 2012, 2012(1):1-21. DOI:10.1155/2012/160724.
[17] Chen C, Chen D, Zhang Y, et al. Changes of CD⁺₄CD₂₅+FOXP3+and CD⁺₈CD₂₈-regulatory T cells in non-small cell lung cancer patients undergoing surgery[J]. Int Immunopharmacol, 2014, 18(2):255-261. DOI:10.1016/j.intimp.2013.12.004.
[18] Zhang GQ, Li F, Sun SJ, et al. Adoptive immunotherapy for small cell lung cancer by expanded activated autologous lymphocytes:a retrospective clinical analysis[J]. As Pac J Cancer Prev, 2015, 16(4):1487-1494. DOI:10.7314/apjcp.2015.16.4.1487.
[19] Joana BN, Bart E. Metabolic stress triggers immune escape by tumors[J]. Trends Cancer, 2019, 5(11):656-658. DOI:10.1016/j.trecan.2019.09.001.
[20] Kim JW, Cochran JR. Targeting ligand-receptor interactions for development of cancer therapeutics[J]. Curr Opin Chem Biol, 2017, 38(1):62-69. DOI:10.1016/j.cbpa.2017.03.010.
[21] Shin DS, Jordan A, Basu S, et al. Regulatory T cells suppress CD⁺₄ T cells through NFAT-dependent transcriptional mechanisms[J]. EMBO Rep. 2014, 15(9):991-999. DOI:10.15252/embr.201338233
[22] Bülent K,OğuzE, Mahmut G, et al. CD⁺₈CD₂₈-cells and CD⁺₄CD₂₅+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients[J]. Med Oncol, 2010, 27(1):29-33. DOI:10.1007/s12032-008-9165-9.
[23] Melanie JM, Anna KN, van der Robbert GM, et al. Peripheral CD₈(+) T cell proliferation is prognostic for patients with advanced thoracic malignancies[J]. Cancer Immunol Immunother, 2013, 62(3):529-539. DOI:10.1007/s00262-012-1360-z.
[24] Lee Y, Auh SL, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD⁺₈ T cells:changing strategies for cancer treatment[J]. Blood, 2009, 114(3):589-595. DOI:10.1182/blood-2009-02-206870.
[25] Zhang T, Yu H, Ni C, et al. Hypofractionated stereotactic radiation therapy activates the peripheral immune response in operable stage Ⅰ non-small-cell lung cancer[J]. Sci Rep, 2017, 7(1):4866. DOI:10.1038/s41598-017-04978-x.
[26] Mccoy MJ, Lake RA, Most RG, et al. Post-chemotherapy T-cell recovery is a marker of improved survival in patients with advanced thoracic malignancies[J]. Br J Cancer, 2012, 107(7):1107-1115. DOI:10.1038/bjc.2012.362.
[27] 李月雅,张翠翠,魏熙胤. 肺癌患者外周血T淋巴细胞亚群NK细胞的基线数值及其与预后的关系[J]. 中国肿瘤临床, 2016, 43(5):204-210. DOI:10.3969/j.issn.1000-8179.2016.05.36.
Li YY, Zhang CC, Wei XY. Base amount of blood T—lymphocyte subsets and NK cells in patients with lung cancer and its value in predicting p rognosis[J]. Chin J Clin Oncol, 2016, 43(5):204-210. DOI:10.3969/j.issn.1000-8179.2016.05.360.
[28] Xuan AN, Peng HU. Immune cells and immune escape of liver cancer[J]. Med Inform, 2011(5):710-713. DOI:10.3969/j.issn.1006-1959.2011.05.687.
[29] Yan L, Wu M, Ba N, et al. Changes in T-lymphocytes in lung cancer patients after hyperthermic intraperitoneal chemotherapy or radiotherapy[J]. Genet Mol Res, 2016, 15(2). DOI:10.4238/gmr.15027865
[30] Mazzola P, Radhi S, Mirandola L, et al. Aging, cancer, and cancer vaccines[J]. Immun Ageing, 2012, 9(1):4. DOI:10.1186/1742-4933-9-4
[31] Liu C, Wu S, Meng X, et al. Predictive value of peripheral regulatory T cells in non-small cell lung cancer patients undergoing radiotherapy[J]. Oncotarget, 2017, 8(26):43427-43438. DOI:10.18632/oncotarget.15238.
[32] Liu C, Jing W, An Ning, et al. Prognostic significance of peripheral CD⁺₈CD⁺₂₈ and CD⁺₈CD^-₂₈T cells in advanced non-small cell lung cancer patients treated with chemo (radio) therapy[J]. J Transl Med, 2019, 17(1):344. DOI:10.1186/s12967-019-2097-7
[33] Saavedra D, Garcia B, Lorenzo-Luaces P, et al. Biomarkers related to immunosenescence:relationships with therapy and survival in lung cancer patients[J]. Cancer Immunol Immunother. 2016, 65(1):37-45. DOI:10.1007/s00262-015-1773-6.
[34] Liu C, Hu QY, Hu K, et al. Increased CD⁺₈CD⁺₂₈ T cells independently predict better early response to stereotactic ablative radiotherapy in patients with lung metastases from non-small cell lung cancer[J]. J Transl Med, 2019, 17(1):120. DOI:10.1186/s12967-019-1872-9.